Cell-Based Therapies Formulations: Unintended components

Author:

Atouf Fouad

Abstract

AbstractCell-based therapy is the fastest growing segment of regenerative medicine, a field that promises to cure diseases not treated by other small molecules or biological drugs. The use of living cells as the active medicinal ingredient present great opportunities to deliver treatment that can trigger the body’s own capacity to regenerate damaged or diseased tissue. Some of the challenges in controlling the quality of the finished cell-therapy product relate to the use of a variety of raw materials including excipients, process aids, and growth promotion factors. The quality of these materials is critical for ensuring the safety and quality of the finished therapeutic products. This review will discuss some of the challenges and opportunities associated with the qualification of excipients as well as that of the ancillary materials used in manufacturing.

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Reference10 articles.

1. <1043> Ancillary materials for cell, gene, and tissue engineered products. In: USP38-NF33. Rockville, MD: US Pharmacopeial Convention; 2016:896.

2. Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs), April 2008. Available at the Food and Drug Administration Web site. http://www.fda.gov, Accessed April 28, 2016

3. Sakamoto N, Tsuji K, Muul LM, Lawler AM, Petricoin EF, Candotti F, et al. Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood. 2007;110(2):501–8.

4. Guidance for industry: nonclinical studies for the safety evaluation of pharmaceutical excipients, May 2005. Available at the Food and Drug Administration Web site. http://www.fda.gov, Accessed April 28, 2016

5. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Q8 Pharmaceutical Development (R2), August 2009. Available at the ICH website: http://www.ich.org, Accessed April 28, 2016

Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3